Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperpolarized 13C,15N2-urea is a metabolically inert imaging agent used as a contrast probe for magnetic resonance imaging (MRI). It consists of urea labeled with the stable isotopes carbon-13 and nitrogen-15, which is hyperpolarized using dissolution dynamic nuclear polarization (DNP) to increase MRI sensitivity by over 10,000-fold compared to conventional MRI. The dual 15N2 labeling is specifically utilized to extend the T1 relaxation time of the hyperpolarized state, significantly improving the signal-to-noise ratio and allowing for a longer imaging window in vivo. This agent is primarily investigated for perfusion imaging applications, including the assessment of brain vasculature, renal function, spinal cord perfusion, and the cancer microenvironment. Unlike gadolinium-based agents, it does not cross the intact blood-brain barrier, making it a sensitive tool for evaluating vascular integrity and perfusion changes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperpolarized 13C,15N2-urea.